Clareo Health | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Lead
Genentech, Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) Performance Status of \<=1
Life expectancy is \>= 3 months
Histologically or cytologically confirmed prostate adenocarcinoma
Disease progression during or following the direct prior line of therapy
Ongoing androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonist or antagonist, or have had bilateral orchiectomy
Metastatic disease
Adequate end organ function
You may not be if
Treatment with any approved systemic anti-cancer therapy within 14 days or 5 drug elimination half-lives
Structurally unstable bone lesions suggest an impending fracture
Untreated central nervous system (CNS) metastases or leptomeningeal disease
Uncontrolled pain
History of malignancy within 5 years
Infection requiring systemic IV antibiotics within 14 days or oral antibiotics within 7 days prior to screening, or any evidence of current infection
Any medical condition or abnormal clinical laboratory finding that, in the investigator's judgment, would preclude the individual's safe participation in and completion of the study or could affect the interpretation of the results
